Freezing prostate tumors shows promise in 354-Patient study

NCT ID NCT03503643

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of life. The goal was to see if this less invasive approach could offer effective disease control with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cryoablation (freezing treatment)
What this could lead to
If successful, this could show that hemi-gland cryoablation is a safe and effective way to control prostate cancer with fewer side effects than whole-gland treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove the treatment is better than others. It also only includes men who chose this procedure, which may limit how well the findings apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.